Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Citodon** is a brand name for a fixed-dose combination tablet containing **paracetamol (acetaminophen) 500 mg** and **codeine phosphate 30 mg**, primarily used for short-term relief of moderate pain not adequately managed by paracetamol or NSAIDs alone. Paracetamol provides analgesic and antipyretic effects through central inhibition of prostaglandin synthesis and possibly other COX-independent mechanisms, while codeine, a prodrug metabolized to morphine by CYP2D6, acts as a weak mu-opioid receptor agonist to enhance pain relief. It is available as effervescent tablets in regions like Sweden, requires a prescription due to opioid content, and carries risks of side effects including constipation, nausea, drowsiness, hypotension, respiratory depression (especially in CYP2D6 ultra-rapid metabolizers), and addiction potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citodon.